BHLHE40

Across TCGA pan-cancer cohorts, BHLHE40 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BHLHE40 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BHLHE40 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated BHLHE40 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where BHLHE40 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	1.000	0.864	.011	9	view →
PDAC	OS	Tertile	All	0.267	0.491	.032	1	view →
LUAD	DFS	Tertile	All	1.000	0.628	.040	1	view →
LSCC	OS	Median	II,III,IV	0.928	1.000	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BHLHE40–HNSC (DFS)

Open the HNSC breakdown →